Justification for Other Than Full and Open Competition – Real Time Location System (RTLS) RFID Asset Tracking and Management Solution (RAF Lakenheath)

1. Contracting Activity:
Defense Health Agency (DHA) Contracting Activity
Healthcare Contracting Division – Southeast (HCD-SE) / Branch 6 – Europe
Landstuhl, Germany

2. Contractor Information:
Conexus Inc.
5250 S Commerce Dr., Suite 160
Salt Lake City, UT 84107-5320
CAGE Code: 1ZBZ3 | UEI: [Redacted]

3. Action Being Approved:
Award of a Firm-Fixed-Price (FFP) contract for a turn-key Real Time Location System (RTLS) asset tracking solution to support the 48th Medical Group Hospital at Royal Air Force (RAF) Lakenheath, United Kingdom, along with associated satellite facilities.

4. Statutory and Regulatory Authority Permitting Other Than Full and Open Competition:

• 10 U.S.C. 3204(a)(1) as implemented by FAR 6.302-1 / RFO 6.103-1 (Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements) and/or FAR 13.501(a) (Simplified Procedures for Certain Commercial Products and Commercial Services – Sole Source / Brand Name Justification).

5. Requirement & Background Summary:
The 48th Medical Group Hospital, RAF Lakenheath, requires an integrated RFID/RTLS solution comprising active tags, passive tags, fixed RFID readers, mobile scanning carts, handheld scanners, enterprise server licensing, turn-key installation, bi-directional APSR (DMLSS / LogiCole) integration, and recurring software and system maintenance. Conexus Inc. is the sole proprietary developer and provider of the Plexus Vision location platform, which holds the active Authority to Operate (ATO) on the Department of Defense Information Network (DoDIN) / DHA Medical Community of Interest (MedCOI), necessary to integrate with existing hospital wireless networks and interface with DMLSS/LogiCole without operational disruption or substantial unrecoverable duplication of cost.

6. Contract Period of Performance:

• Base Period of Performance: 16 September 2026 – 15 September 2027

• Total Period of Performance (if all options exercised): 16 September 2026 – 15 September 2031

7. Public Posting / Redaction Notice:
In accordance with FAR 6.305 / RFO 6.301 / FAR 13.501, the redacted Justification and Approval (J&A) document is attached to this notice. Proprietary business information and sensitive details have been redacted pursuant to the Freedom of Information Act (FOIA), 5 U.S.C. 552(b)(4).